Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 156

Similar articles for PubMed (Select 20962613)

1.

Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication.

Chun TW, Justement JS, Murray D, Hallahan CW, Maenza J, Collier AC, Sheth PM, Kaul R, Ostrowski M, Moir S, Kovacs C, Fauci AS.

AIDS. 2010 Nov 27;24(18):2803-8. doi: 10.1097/QAD.0b013e328340a239.

2.

HIV reservoir dynamics in the face of highly active antiretroviral therapy.

Costiniuk CT, Jenabian MA.

AIDS Patient Care STDS. 2015 Feb;29(2):55-68. doi: 10.1089/apc.2014.0173. Epub 2014 Nov 20.

PMID:
25412339
3.

Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication.

Le T, Farrar J, Shikuma C.

AIDS. 2011 Mar 27;25(6):871-2; author reply 872-3. doi: 10.1097/QAD.0b013e32834490b1. No abstract available.

PMID:
21412062
4.
5.

Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy.

Chun TW, Murray D, Justement JS, Hallahan CW, Moir S, Kovacs C, Fauci AS.

J Infect Dis. 2011 Jul 1;204(1):135-8. doi: 10.1093/infdis/jir208.

6.

HIV reservoirs: pathogenesis and obstacles to viral eradication and cure.

Chun TW, Fauci AS.

AIDS. 2012 Jun 19;26(10):1261-8. doi: 10.1097/QAD.0b013e328353f3f1. Review.

PMID:
22472858
7.
8.

Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials.

Mexas AM, Graf EH, Pace MJ, Yu JJ, Papasavvas E, Azzoni L, Busch MP, Di Mascio M, Foulkes AS, Migueles SA, Montaner LJ, O'Doherty U.

AIDS. 2012 Nov 28;26(18):2295-306. doi: 10.1097/QAD.0b013e32835a5c2f.

PMID:
23014521
9.

CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy.

Boulassel MR, Chomont N, Pai NP, Gilmore N, Sékaly RP, Routy JP.

J Clin Virol. 2012 Jan;53(1):29-32. doi: 10.1016/j.jcv.2011.09.018. Epub 2011 Oct 22.

PMID:
22019250
10.

Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy.

Chun TW, Davey RT Jr, Ostrowski M, Shawn Justement J, Engel D, Mullins JI, Fauci AS.

Nat Med. 2000 Jul;6(7):757-61.

PMID:
10888923
11.

Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells.

Buzon MJ, Martin-Gayo E, Pereyra F, Ouyang Z, Sun H, Li JZ, Piovoso M, Shaw A, Dalmau J, Zangger N, Martinez-Picado J, Zurakowski R, Yu XG, Telenti A, Walker BD, Rosenberg ES, Lichterfeld M.

J Virol. 2014 Sep 1;88(17):10056-65. doi: 10.1128/JVI.01046-14. Epub 2014 Jun 25.

12.

Modeling HIV persistence, the latent reservoir, and viral blips.

Rong L, Perelson AS.

J Theor Biol. 2009 Sep 21;260(2):308-31. doi: 10.1016/j.jtbi.2009.06.011. Epub 2009 Jun 17. Review.

13.

A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy.

Deeks SG, Wagner B, Anton PA, Mitsuyasu RT, Scadden DT, Huang C, Macken C, Richman DD, Christopherson C, June CH, Lazar R, Broad DF, Jalali S, Hege KM.

Mol Ther. 2002 Jun;5(6):788-97.

14.

The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy.

Lerner P, Guadalupe M, Donovan R, Hung J, Flamm J, Prindiville T, Sankaran-Walters S, Syvanen M, Wong JK, George MD, Dandekar S.

J Virol. 2011 May;85(10):4772-82. doi: 10.1128/JVI.02409-10. Epub 2011 Feb 23.

15.

Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies.

Chun TW, Justement JS, Moir S, Hallahan CW, Ehler LA, Liu S, McLaughlin M, Dybul M, Mican JM, Fauci AS.

Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):253-8.

16.

Early initiation of combination antiretroviral therapy in HIV-1-infected newborns can achieve sustained virologic suppression with low frequency of CD4+ T cells carrying HIV in peripheral blood.

Bitnun A, Samson L, Chun TW, Kakkar F, Brophy J, Murray D, Justement S, Soudeyns H, Ostrowski M, Mujib S, Harrigan PR, Kim J, Sandstrom P, Read SE.

Clin Infect Dis. 2014 Oct;59(7):1012-9. doi: 10.1093/cid/ciu432. Epub 2014 Jun 9.

PMID:
24917662
17.

Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial).

Stellbrink HJ, van Lunzen J, Westby M, O'Sullivan E, Schneider C, Adam A, Weitner L, Kuhlmann B, Hoffmann C, Fenske S, Aries PS, Degen O, Eggers C, Petersen H, Haag F, Horst HA, Dalhoff K, Möcklinghoff C, Cammack N, Tenner-Racz K, Racz P.

AIDS. 2002 Jul 26;16(11):1479-87. Erratum in: AIDS 2002 Oct 18;16(15):2103.

PMID:
12131185
18.

Residual human immunodeficiency virus type 1 infection in lymphoid tissue during highly active antiretroviral therapy: quantitation and virus characterization.

Dyrhol-Riise AM, Voltersvik P, Berg OG, Olofsson J, Kleivbo S, Asjö B.

AIDS Res Hum Retroviruses. 2001 May 1;17(7):577-86.

PMID:
11375053
19.

HIV-1 DNA and RNA kinetics in primary HIV infection.

Lillo F, Grasso M, Lodini S, Capiluppi B, Lazzarin A, Tambussi G.

J Biol Regul Homeost Agents. 2002 Jan-Mar;16(1):49-52.

PMID:
12003174
20.

Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size.

Jain V, Hartogensis W, Bacchetti P, Hunt PW, Hatano H, Sinclair E, Epling L, Lee TH, Busch MP, McCune JM, Pilcher CD, Hecht FM, Deeks SG.

J Infect Dis. 2013 Oct 15;208(8):1202-11. doi: 10.1093/infdis/jit311. Epub 2013 Jul 12.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk